First authors of the article -Jeff Weitz/Hamilton Health Sciences; Robert Harrington/Weill Cornell Medicine
May 2, 2026, 13:10
Targeting FXIa As a Safer Anticoagulant Target Than FXa in LIBREXIA Trial – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by et al, adding:
”Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
This narrative review details the pharmacological rationale for targeting FXIa as a safer anticoagulant target than FXa, and outlines how phase 2 findings informed milvexian dosing regimens across three phase 3 LIBREXIA trials enrolling approximately 50,000 patients with AF, ACS, or ischemic stroke.”
Title: Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
Authors: Jeff Weitz, Robert Harrington on behalf of the LIBREXIA Program Executive Council
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI